stockrow
Monday 9 November 2026
Export PYXS’s income statement to Excel — free account
Pyxis Oncology, Inc.
PYXSPyxis Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $13.9 million, down 14.2% from fiscal 2024.
- EPS
- −33.3%
- Free cash flow
- −5.46%
Quarter to June 2026, against a year earlier
1.66
0.05
+3.11%
Follow PYXS
Alert me
Pyxis Oncology, Inc. (PYXS) P/E ratio
Pyxis Oncology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.3× (April 2022) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Dec 2025 | 0.0× | — |
| Jun 2025 | 0.0× | — |
| Mar 2024 | 0.0× | — |
Against its own ten years
Low 0.0×
High 0.3×
Ten-year median
0.0×
Current reading's percentile
85
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| ELDN Eledon Pharmaceuticals, Inc. compare | n/m |
| RNA Atrium Therapeutics, Inc. compare | n/m |
| KROS Keros Therapeutics, Inc. compare | n/m |
| IFRX InflaRx N.V. compare | n/m |
| IKT Inhibikase Therapeutics, Inc. compare | n/m |
| PYXS Pyxis Oncology, Inc. | n/m |
| ARTV Artiva Biotherapeutics, Inc. compare | n/m |
| PRQR ProQR Therapeutics N.V. compare | n/m |
| PALI Palisade Bio, Inc. compare | 1.7× |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)